CYP 3A 5 and MDR1 Gene Polymorphisms is Associated with Pharmacokinetic Variation of Tacrolimus in Renal Transplant Patients

张鑫,刘志红,郑敬民,陈朝红,唐政,陈劲松,黎磊石

DOI: https://doi.org/10.3969/j.issn.1006-298x.2004.04.003

2004-01-01

Abstract:Objective:Tacrolimus is an immunosuppressive drug with narrow window of therapeutic dosage range. The wide interindividual variation of tacrolimus' pharmacokinetics is concerned with its clinical application and efficacy. CYP3A and P-glycoprotein(P-gp, encoded by MDR1) are involved in its pharmocokinetics by their effect on the metabolism of tacrolimus or on the muccosal absorption. In this study, we evaluated whether the CYP3A5 *1/*3 polymorphism or the MDR1 C3435T polymorphism were associated with tacrolimus concentration/dose ratio. Methodology:CYP3A5 and MDR1 genotypes were determined by polymerase chain reaction followed by restriction fragment length polymorphism analysis in 118 adult renal transplant patients receiving tacrolimus. Tacrolimus tough concentration was measured by ELISA and concentration/dose ratio was determined at the 7th day, the end of the 1st month and the end of the 3rd month after renal transplantation. Results:The concentration/dose ratios of CYP3A5 *1/*1 and *1/*3 patients were significantly lower than those of *3/*3 patients at the 7th day, the end of the 1st month and the end of the 3rd month after translation. There was mild difference between *1/*1 homozygotes and *1/*3 heterozygotes at 1 and 3 months after operation. No difference was found among the MDR1 genotypes. Conclusion:CYP3A5 *1/*3 polymorphism are associated with tacrolimus pharmacokinetics and dose requirements in renal transplant recipients. Clinical application of the gene polymorphism and pharmacogenetic studies will be of clinical significance in the individulization of tacrolimus dosage.